A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00564954 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Dex-methylphenidate hydrochloride extended-release (Focalin XR)
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals